Management of mild and severe gastro‐oesophageal reflux disease
- 3 June 2003
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (s2) , 52-56
- https://doi.org/10.1046/j.1365-2036.17.s2.5.x
Abstract
Treatment of endosocopy-negative gastro-oesophageal reflux disease (s-GERD) should be directed towards rapid relief of symptoms and then maintenance of relief using minimum yet effective therapy. Responses to proton pump inhibitors are somewhat lower in s-GERD patients compared to GERD with overt erosive damage (e-GERD). The reasons for a lower response rate are not clear but may relate to the inclusion of patients who do not have reflux disease or patients with a lower oesophageal sensory threshold. Also poorly understood is the lower yield of complete heartburn relief when the number of associated dyspeptic symptoms is high. Some form of long-term therapy is needed in the majority of patients. 'On demand' proton pump inhibitor therapy to control reflux symptoms is a new and attractive option. Time to study discontinuation due to insufficient control of heartburn, or any other reason resulting in unwillingness to continue with on-demand therapy, is a pragmatic outcome that is well suited to definition of the efficacy of on-demand therapy. The goals of treatment of e-GERD should be to relieve symptoms and to heal lesions. Symptom severity and much less endoscopic abnormalities drives the therapeutic choices. When symptoms are mild or intermittent and when oesophagitis is of limited degree, standard dose proton pump inhibitor is usually instituted. Fewer and fewer clinicians would still opt for an H2-receptor antagonist. If there is moderate or severe oesophagitis or if symptoms are particularly troublesome, then the patient should start with standard-dose proton pump inhibitor therapy once a day, but not uncommonly a b.d. dosage maybe necessary. Once the dose of the acid suppressant that relieves symptoms is found, this dose should be maintained for a period of 3 months. After this time, an attempt should be made to reduce the dose. If symptoms recur, then the patients should go back to the full-dose proton pump inhibitor and a plan should be formulated for long-term treatment. The long-term treatment options vary between ongoing acid and suppressant therapy, with occasional attempts to reduce the dose, or to go for 'on demand' therapy and (rarely) includes consideration for surgery or endoscopic anti-reflux therapKeywords
This publication has 36 references indexed in Scilit:
- Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study resultsAlimentary Pharmacology & Therapeutics, 2003
- EsomeprazoleDrugs, 2002
- Evidence for Therapeutic Equivalence of Lansoprazole 30mg and Esomeprazole 40mg in the Treatment of Erosive OesophagitisClinical Drug Investigation, 2002
- Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trialAlimentary Pharmacology & Therapeutics, 2000
- Rabeprazole, 20 mg Once Daily or 10 mg Twice Daily, Is Equivalent to Omeprazole, 20 mg Once Daily, in the Healing of Erosive Gastrooesophageal Reflux DiseaseScandinavian Journal of Gastroenterology, 2000
- On demand therapy with omeprazole for the long‐term management of patients with heartburn without oesophagitis—a placebo‐controlled randomized trialAlimentary Pharmacology & Therapeutics, 1999
- Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1999
- Gastro-oesophageal reflux disease in primary careEuropean Journal of Gastroenterology & Hepatology, 1998
- Omeprazole 10 Milligrams Once Daily, Omeprazole 20 Milligrams Once Daily, or Ranitidine 150 Milligrams Twice Daily, Evaluated as Initial Therapy for the Relief of Symptoms of Gastro-oesophageal Reflux Disease in General PracticeScandinavian Journal of Gastroenterology, 1997
- Symptom index as a marker of gastro-oesophageal reflux diseaseBritish Journal of Surgery, 1992